Implantation of pancreatic islet into the paranasal sinuses as a noninvasive cell therapy for diabetes
Innovative Products and Technologies
Technology Offer
Implantation of pancreatic islet into the paranasal sinuses as a noninvasive cell therapy for diabetes
- RAMOT at Tel Aviv University Ltd.
- From Israel
- Responsive
- Innovative Products and Technologies
Summary of the technology
The long-term goal of the proposed project is to create a noninvasive or minimaly invasive technology for cell therapy of diabetes. Such technology will be used for conduction of clinical trials with pancreatic islets implantation in paranasal sinuses (PNS) of patients with insulin dependent diabetes (IDDM), allowing minimal patient discomfort with easy insertion, as well as simple removal and exchange of implant.
The specific aim of this project is to achieve a proof of concept for successful islet implantation into PNS using animal model of diabetes.
Milestones will include achievement of long-term normoglycemia after syngeneic and allogeneic islet transplantation into PNS of diabetic rats, as well as evaluation of the exact islet localization, morphology and integration with PNS tissues.
Preliminary results obtained by the research team indicate that transplantation of insulin-producing beta cell line (INS-1) into PNS of streptozotocin-induced diabetic rats lead to normoglycemia during first week of post implantation period. In this initial experiments the implanted animals developed hypoglycemia due to poor insulin regulation of insulinoma cells. Immunohistochemical analysis of this implant showed insulin staining of insulinoma cells localized in air-filled PNS and intensive neovascularization of grafted tissue.
Ongoing pilot study of syngeneic islet implantation in PNS of diabetic rats showed reversal of diabetes two days after implantation of 2500-3000 islet equivalents, with sustained normoglycemia for at least one month. In addition, implanted animals showed body mass gain and normal glucose tolerance test.
Project ID : 2-2012-343
Details of the Technology Offer
The long-term goal of the proposed project is to create a noninvasive or minimaly invasive technology for cell therapy of diabetes. Such technology will be used for conduction of clinical trials with pancreatic islets implantation in paranasal sinuses (PNS) of patients with insulin dependent diabetes (IDDM), allowing minimal patient discomfort with easy insertion, as well as simple removal and exchange of implant.
The specific aim of this project is to achieve a proof of concept for successful islet implantation into PNS using animal model of diabetes.
Milestones will include achievement of long-term normoglycemia after syngeneic and allogeneic islet transplantation into PNS of diabetic rats, as well as evaluation of the exact islet localization, morphology and integration with PNS tissues.
Preliminary results obtained by the research team indicate that transplantation of insulin-producing beta cell line (INS-1) into PNS of streptozotocin-induced diabetic rats lead to normoglycemia during first week of post implantation period. In this initial experiments the implanted animals developed hypoglycemia due to poor insulin regulation of insulinoma cells. Immunohistochemical analysis of this implant showed insulin staining of insulinoma cells localized in air-filled PNS and intensive neovascularization of grafted tissue.
Ongoing pilot study of syngeneic islet implantation in PNS of diabetic rats showed reversal of diabetes two days after implantation of 2500-3000 islet equivalents, with sustained normoglycemia for at least one month. In addition, implanted animals showed body mass gain and normal glucose tolerance test.
The specific aim of this project is to achieve a proof of concept for successful islet implantation into PNS using animal model of diabetes.
Milestones will include achievement of long-term normoglycemia after syngeneic and allogeneic islet transplantation into PNS of diabetic rats, as well as evaluation of the exact islet localization, morphology and integration with PNS tissues.
Preliminary results obtained by the research team indicate that transplantation of insulin-producing beta cell line (INS-1) into PNS of streptozotocin-induced diabetic rats lead to normoglycemia during first week of post implantation period. In this initial experiments the implanted animals developed hypoglycemia due to poor insulin regulation of insulinoma cells. Immunohistochemical analysis of this implant showed insulin staining of insulinoma cells localized in air-filled PNS and intensive neovascularization of grafted tissue.
Ongoing pilot study of syngeneic islet implantation in PNS of diabetic rats showed reversal of diabetes two days after implantation of 2500-3000 islet equivalents, with sustained normoglycemia for at least one month. In addition, implanted animals showed body mass gain and normal glucose tolerance test.